Prevention of cardiac allograft arteriosclerosis using antisense proliferating-cell nuclear antigen oligonucleotide

Transplantation

Volumn 70, Issue 2, 2000, Pages 398-400

  Suzuki, Jun Ichi ^a,b   Isobe, Mitsuaki ^a   Morishita, Ryuichi ^c   Nishikawa, Toshio ^d   Amano, Jun ^a   Kaneda, Yasufumi ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG MECHANISM; GRAFT OCCLUSION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

EID: 0034721051     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200007270-00031     Document Type: Article

References (13)

1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report-1998. J Heart Lung Transplant 1998; 17: 656.
2. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069.
3. Schwartz SM, Reidy MA, O'Brien ER. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 1995; 74: 541.
4. Suzuki J, Isobe M, Morishita R, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997; 3: 900.
5. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474.
6. Yamaguchi M, Hayashi Y, Hirose F, et al. Molecular cloning and structural analysis of mouse gene and pseudogenes for proliferating cell nuclear antigen. Nucleic Acids Res 1991; 19: 2403.
7. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 1994; 149: 13.
8. Morishita R, Gibbons GH, Ellison KE, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458.
9. Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: a comparative study with captopril. Circulation 1996; 93: 333.
10. Suzuki J, Isobe M, Yamazaki S, Horie S, Okubo S, Sekiguchi M. Inhibition of accelerated coronary atherosclerosis with short-term blockade of ICAM-1 and LFA-1 in a heterotopic murine model of cardiac transplantation. J Heart Lung Transplant 1997; 16: 1141.
11. Akai Y, Iwano M, Kitamura Y, et al. Intraglomerular expressions of IL-1 alpha and platelet-derived growth factor (PDGF-B) mRNA in experimental immune complex-mediated glomerulonephritis. Clin Exp Immunol 1994; 95: 29.
12. Patel GV, Shum-siu A, Henifold BW, Wieman TJ, Hendler FJ. Detection of epidermal growth factor receptor mRNA in tissue sections from biopsy specimens using in situ polymerase chain reaction. Am J Pathol 1994; 144: 7.
13. Castier Y, Chemla E, Nierat J, et al. The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific. J Cardiovasc Surg 1998; 39: 1.